Sun Yat-sen University Cancer Center

Name: Liru He

Title: Chief physician, doctoral supervisor, attending professor

Email:

Phone:

share

Profile

I．Academic Appointments
Council Member of the Chinese Anti-Cancer Association
Chairman of CACA Prostate Cancer Integrative Chinese and Western Medicine Committee
Vice Chairman of the Integrative Prostate Cancer Committee, CACA
Standing Committee Member of the Integrative Chinese and Western Medicine for Bladder Cancer Professional Committee, CACA
Standing committee member of CSCO Urothelial Carcinoma Committee
Member of the CSCO Prostate Cancer Committee, Member of the CSCO Renal Cell Carcinoma Committee
Committee Member, Prostate Cancer Quality Control Committees, National Cancer Quality Control Center
Committee Member, Renal Cancer Quality Control Committees, National Cancer Quality Control Center

II.Research Projects
1．National Natural Science Foundation of China, General Program, 82373210, "Study on the Role and Mechanism of Tumor-Associated Fibroblasts in Regulating Ferroptosis-Mediated Radiotherapy Resistance in Renal Cell Carcinoma via CXCL12 Release," January 1, 2024 – December 31, 2027, 480,000 RMB, Principal Investigator
2．Guangdong Provincial Fund for Basic and Applied Basic Research, General Project, 2023A1515010391, "Study on the Role and Mechanism of PUF60 in Inhibiting Pyroptosis-Induced Radiotherapy Resistance in Bladder Cancer by Suppressing HMGB1 and Reducing Caspase1/GSDMD Activity," January 2023–December 2025, 100,000 RMB, Principal Investigator

Interests

III.Basic Information
Specializes in precision radiotherapy and multidisciplinary comprehensive treatment for urological tumors, including prostate cancer, renal cell carcinoma, and urothelial carcinoma.
She has led multiple research projects funded by the National Natural Science Foundation of China and has published over 40 SCI-indexed papers.
She serves as chair of CACA Prostate Cancer Integrative Chinese and Western Medicine Committee, standing committee member of CSCO Urothelial Carcinoma Committee, and committee member of CSCO Renal Cell Carcinoma Committee.
She has been honored as a "People's Good Doctor" and recognized as an outstanding expert model in the field of urological oncology.

IV. Clinical trials
1. Preliminary results from a phase II study comparing sunitinib alone or with stereotactic body radiotherapy (SBRT) for newly diagnosed oligometastatic renal cell carcinoma
https://ascopubs.org/doi/pdf/10.1200/JCO.2023.41.16_suppl.4533
2. Phase II Trial of Camrelizumab plus Apatinib in Combination with Stereotactic Body Radiotherapy (SBRT) in Patients with Recurrent/Metastatic Non–Clear-Cell Renal Cell Carcinoma (nccRCC)
https://ascopubs.org/doi/pdf/10.1200/JCO.2023.41.16_suppl.e16531
3. Preliminary results from a phase II clinical study of first-line drugs combined with stereotactic body radiotherapy (SBRT) in the treatment of oligoprogressive renal cell carcinoma
https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.4540
4. Phase II clinical study of the safety and efficacy of sintilimab in combination with axitinib and stereotactic radiotherapy in the treatment of local-regional recurrent renal cell cancer
https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.e16511
5. A Phase II Clinical Study of Axitinib and Toripalimab Combined with Stereotactic Radiation (SBRT) for Metastatic Renal Cell Carcinoma (mRCC) after Oligoprogression from First-Line Anti-Angiogenic Therapy
https://doi.org/10.1016/j.ijrobp.2024.07.1188
6. MRI-Guided Adaptive SBRT for Kidney and Adrenal Gland Tumors: An Analysis of the Intra-Fractional Tumor Motion and Inter-Fractional Dosimetric Impact
https://doi.org/10.1016/j.ijrobp.2024.07.1145
7. Phase ll Clinical Study of the Safety and Efficacy of Sintilimab in Combination with Axitinib and Stereotactic Radiotherapy in the Treatment of Local-regional Recurrent Renal cell cancer
https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16511
8. A Phase ll clinical Study of camrelizumab plus Apatinib in combination with Stereotactic Body Radiotherapy (SBRT) for Advanced Non-clear Cell Renal Cell Carcinoma(nccRcC)
https://ascopubs.org/doi/10.1200/JCO.2025.43.5_suppl.557

Education

September 2000 – June 2007, Sun Yat-sen University, Seven-Year Clinical Medicine Program (Bachelor's and Master degree）
July 2007 – December 2010, Resident physician，Radiation Oncology Department, Sun Yat-sen University Cancer Center
December 2010 – December 2015, Chief Physician, Cancer Center of Sun Yat-sen University
September 2011 – June 2016, Sun Yat-sen University, Doctor's degree
September 2013 – September 2014, Visiting Scholar, Department of Radiation Oncology, M.D. Anderson Cancer Center, USA
December 2015 – December 2020, Associate Chief Physician, Department of Radiation Oncology, Sun Yat-sen University Cancer Center
September 2020 to present, Chief Physician, Department of Radiation Oncology, Sun Yat-sen University Cancer Center

Publications

1.Liu Y, Zhang XY, Wei WS, Liu RQ, Pan QW, Zhang YJ, Li JB, Peng YL, Huang TX, Zhang ZL, Han H, Guo SJ, Gao JM, Zhou FJ, Dong P, He L (corresponding author). Stereotactic body radiotherapy plus sunitinib versus sunitinib alone in treatment-naive oligometastatic renal cell carcinoma: A phase 2 clinical trial. Cell Rep Med. 2026 May 19;7(5):102747.

2. Cai L, Chen K, Pan Q, Zhang X, Liu R, Liu Y, Gao J, Zhang Z, Zhou F, Dong P, Tian L, He L (corresponding author). Response evaluation and tumor shrinkage pattern after SBRT for renal cell carcinoma. Radiother Oncol. 2025 May;206:110802.

3. Pan Q, Liu R, Zhang X, Cai L, Li Y, Dong P, Gao J, Liu Y, He L (corresponding author). CXCL14 as a potential marker for predicting immunotherapy response in renal cell carcinoma. Ther Adv Med Oncol. 2023 Dec 25;15:17588359231217966.

4. Pan, Q., Lin, F., Liu, R., Li, Y., Zhang, X., Luo, R., Cai, L., Liu, Y., Deng, W., He, L. (corresponding author). Fe/Ni layered double hydroxide biocatalysts inhibit tumor growth through ROS and ferroptosis signaling pathways. Chem. Eng. J. 2023(466): 142962.

5. Dong P, Zhang X, Peng Y, Zhang Y, Liu R, Li Y, Pan Q, Wei W, Guo S, Zhang Z, Han H, Zhou F, Liu Y, He L (corresponding author). Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. Clin Cancer Res. 2022 Nov 1;28(21):4807-4819.

6. Liu Y, Long W, Zhang Z, Mai L, Huang S, Liu B, Cao W, Wu J, Zhou F, Li Y, He L (corresponding author). Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistant prostate cancer: a single-center experience. Radiat Oncol. 2021 Jan 6;16(1):5.

7. Liu Y, Long W, Zhang Z, Zhang Z, Mai L, Huang S, Han H, Zhou F, Dong P, He L (corresponding author). Metastasis-directed stereotactic body radiotherapy for oligometastatic renal cell carcinoma: extent of tumor burden eradicated by radiotherapy. World J Urol. 2021 Nov;39(11):4183-4190.

8. Li Z, Zhang Y, Sui S, Hua Y, Zhao A, Tian X, Wang R, Guo W, Yu W, Zou K, Deng W, He L (co-corresponding author), Zou L. Targeting the HMGB3/hTERT axis for radioresistance in cervical cancer. J Exp Clin Cancer Res. 2020 Nov 13;39(1):243.

9. Peng X, Zhou S, Liu S, Li J, Huang S, Jiang X, Lin M, Huang S, Lin C, Qian C, Liu M, He L (corresponding author). Dose-volume analysis of predictors for acute anal toxicity after radiotherapy in prostate cancer patients. Radiat Oncol. 2019 Oct 10;14(1):174.

10. Zhou S, Luo L, Li J, Lin M, Chen L, Shao J, Lu S, Ma Y, Zhang Y, Chen W, Liu M, Liu S, He L (corresponding author). Analyses of the factors influencing the accuracy of three-dimensional ultrasound compared with cone-beam CT in image-guided radiotherapy for prostate cancer with or without pelvic lymph node irradiation. Radiat Oncol. 2019 Jan 29;14(1):22.

Our Experts